CREBBP and prostate neoplasm: Lasko and colleagues reported a selective catalytic p300/CBP inhibitor able to downregulate the AR transcriptional program both in castration-sensitive and castration-resistant prostate tumors and to inhibit tumor growth in CRPC xenograft models [94], while Jin and colleagues found that targeting the p300/CBP bromodomain had remarkably similar effetcs [41].